NK Cell Therapy After Cancer Treatment: What to Know in Japan

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

Completing surgery, chemotherapy, or radiation therapy is a major milestone, but many people say the weeks and months afterward bring a new kind of uncertainty. Questions about recurrence, fatigue, and long-term health are common, and some patients begin to look into supportive options that work alongside their regular follow-up care. NK (natural killer) cell therapy is one such option offered in Japan. This article explains how it is positioned for people who have finished standard treatment, what it can and cannot be expected to do, and what international patients may wish to prepare before considering it at Grand Green Osaka Umekita Clinic.

The short answer: it is an option to discuss, not a replacement for follow-up care

NK cell therapy can be received with the aim of supporting immune function and, in some cases, with recurrence prevention in mind after cancer treatment. However, it is important to be realistic. No immune cell therapy can guarantee that cancer will not return, and it should never be seen as a substitute for the surveillance, imaging, blood tests, and medications recommended by your oncology team. The most sensible way to think about it is as an additional option that you consider together with your doctors, not as a reason to change or skip any part of your standard care.

It is also a private, self-pay treatment in Japan. It is not covered by national health insurance, and the details of eligibility, expected benefit, risks, and costs must be confirmed through a consultation with a physician who has reviewed your own medical history.

Why the immune system matters after treatment

NK cells are a type of lymphocyte that circulates in the blood. They belong to the innate immune system, which means they can recognize and attack abnormal cells, including cancer cells and virus-infected cells, without waiting for instructions from other immune cells. Researchers describe this ongoing process as immune surveillance. Even in healthy people, abnormal cells are thought to arise regularly, and the immune system is believed to remove most of them before they become a problem.

The activity of NK cells is known to decline with age, with prolonged stress, and with the effects of cancer itself. Cancer treatments can also place a heavy burden on the body. This is the background for the idea behind NK cell therapy: if the number and activity of NK cells can be increased and then returned to the body, immune function may be reinforced. It is worth stressing that this is a concept supported by laboratory and early clinical research, and that evidence on actual outcomes varies by cancer type and study design. A single study should never be taken as proof for an individual patient.

How the treatment works in practice

The therapy uses your own cells, which is called an autologous approach. First, a standard blood sample is taken at the clinic. The blood is sent to a specialized cell processing facility, where NK cells are activated and expanded over a period of culture. The cultured cells are then returned to your body by intravenous infusion, similar to a regular drip.

Because treatment consists of a blood draw and an infusion, hospitalization is generally not required, and many patients are able to continue their daily routines. Since your own cells are used, the risk of rejection is considered low, and serious side effects have rarely been reported. Even so, temporary reactions such as fever or fatigue can occur, and individual responses differ. Your doctor will explain what to watch for and when to get in touch after an infusion.

Working alongside your oncology team

NK cell therapy is generally considered compatible with surgery, chemotherapy, and radiation therapy, so it may be considered alongside them, with timing coordinated by your doctors. For someone who has already completed those treatments, the practical question is usually about coordination rather than compatibility. Your oncologist at home knows the details of your diagnosis, stage, pathology, and treatment history, and that information is essential for any physician in Japan who evaluates whether NK cell therapy is suitable for you.

Many international patients find it helpful to be open with their home doctors about their interest. A good conversation is not about asking permission to abandon follow-up, but about agreeing on how regular check-ups and tests will continue. The clinic can also coordinate with the medical institution that provides your standard treatment when this is appropriate and you have given your consent.

Safety management and legal framework in Japan

In Japan, cell therapies of this kind are provided under the Act on the Safety of Regenerative Medicine. Clinics submit a treatment plan that is reviewed by a certified committee and then submitted to the Ministry of Health, Labour and Welfare, and the cells are processed at licensed facilities. This framework sets requirements for safety management and for explaining the treatment to patients. It does not mean that the effectiveness of a therapy is proven or guaranteed, and it is reasonable to ask the clinic directly how the framework applies to the treatment being offered to you.

Questions to prepare before you travel to Osaka

If you are thinking about a consultation in Osaka, a little preparation makes the visit far more useful. Consider gathering the following and discussing them with your doctors:

• A summary of your diagnosis, stage, and treatments completed, ideally with a translated or English-language report
• Recent blood test results and imaging reports, and your current follow-up schedule
• A list of medications and supplements you take, as well as any allergies
• Your own goals: for example, supporting immune function, or reducing worry about recurrence
• Questions about the number of infusions, the treatment period, costs, risks, and possible side effects

Because the therapy is a self-pay treatment, you should receive a clear explanation of fees and what they include before you decide anything. Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka, which is convenient for travelers, and the clinic provides information pages for international patients in multiple languages, as well as ways to make inquiries in advance. It is perfectly reasonable to take time to think things over, and to compare what you hear in Japan with the advice of your own oncology team.

Key points to remember

NK cell therapy is an immune cell therapy that uses your own cells and may be considered after standard cancer treatment, with the aim of supporting immune function or recurrence prevention. It cannot promise that cancer will not come back, and it does not replace regular follow-up or standard treatment. Suitability, expected benefits, risks, side effects, and fees can only be determined by a physician after reviewing your medical history, so a consultation is the right first step. If you are in the position of looking beyond your current care, gather your records, speak openly with your home oncologist, and use your consultation to ask every question that matters to you.

• Uses your own NK cells
• Not a replacement for care
• Coordinate with your doctors
• Confirm at a consultationEligibility, risks and fees

This diagram is a conceptual summary of the article

References

• PubMed: Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. (1991)
• PMC: Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer. (2022)
• PMC: Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review. (2023)
• PMC: Toll-like receptor agonists in cancer therapy. (2009)
• PMC: The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial. (2010)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.